A group of Blue Cross Blue Shield insurers is investing $55 million in a venture that aims to offer cheaper prices to their members on generic drugs that currently have little or no competition, the companies said on Thursday.
Trending:
Blues health insurers put up $55 million to take on generic drugmakers